An interventional study of Escitalopram and Escitalopram+Aripiprazole in Outpatients / Inpatients With Depression, sponsored by Peking University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by Peking University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 7 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.
Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 25th largest by planned enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2022, is one of 17 with no phase, and was the 90th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Medical University of Vienna · Sites in Austria
Ages 18–65 · Healthy volunteers
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19–65
NYU Langone Health · Sites in United States
Ages 60+
By country, each count listing its studies:
Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 21 · Phase 4 53
First in 2002; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 252 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 80 across the 99 interventional studies. Of the 76 that completed or were terminated, 41 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 100 have an industry lead sponsor. The 10 most frequent:
Peking University is the lead sponsor of 420 studies on the registry; 124 are open to participants now.
Peking University has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
4 of the studies testing escitalopram in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06675851Medical University of ViennaReward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People | 2026-12 |
| NCT05004987NYU Langone HealthAβ Dynamics in LLMD | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 100 studies testing escitalopram in Depressive Disorder, Major, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.
Major depressive disorder (MDD) is a heterogeneious psychiatric disorder with complex etiology and pathogenesis. The lack of objective criteria for diagnosis and the use of trial-and-error treatment strategy are the current challenge. Anhedonia is the core symptom of MDD and the aberrant reward system and abnormal inflammatory immune may be the pathological mechanisms. Previous evidence suggests anhedonia cannot be improved quickly and efficiently by taking the first-line antidepressants. This study focuses on exploring the optimal diagnosis and treatment strategy for MDD patients with anhedonia. Based on the hypothesis of inflammatory-immune system,neurotransmitter abnormalities and aberrant reward system, this study aims to evaluate the efficacy and safety of the combinations of escitalopram and aripiprazole and/or omega-3 polyunsaturated fatty acids for MDD patients with anhedonia with a factorial design. Moreover, the multidimensional data including the clinicopathological features, neuroimaging data (MRI) and inflammatory cytokines will be used to establish the model of diagnosis and treatment strategy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Escitalopram monotherapy (10-20 mg/day)
Drug: Escitalopram
Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)
Drug: Escitalopram+omega-3 PUFAs
Escitalopram (10-20 mg/day)combined with Aripiprazole (2.5-10 mg/day)
Drug: Escitalopram+Aripiprazole
Escitalopram (10-20 mg/day)combined with omega-3 PUFAs (EPA 900mg,DHA 300 mg)and Aripiprazole (2.5-10 mg/day)
Drug: Escitalopram+Aripiprazole+omega-3 PUFAs
Escitalopram
Drug pages: EscitalopramStudies of EscitalopramEscitalopram pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AripiprazoleStudies of AripiprazoleAripiprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Escitalopram+Aripiprazole
Escitalopram+omega-3 PUFAs
Escitalopram+Aripiprazole+omega-3 PUFAs
17-item Hamilton depression rating scale (HAMD-17) value
The value of 17-item Hamilton depression rating scale (HAMD-17) total score treatment compared to that at the baseline. The maximum score of HAMD-17 is 51 and the minimum is 0. Higher scores mean a worse outcome.
Time frame: Day 0 to Day 56
Anhedonia level-Dimensional Anhedonia Rating Scale (DARS)
The outcome is measured by Dimensional Anhedonia Rating Scale (DARS) total score. The maximum score of DARS total score is 68 and the minimum is 0. Higher scores mean a better outcome.
Time frame: Day 0 to Day 56
Anxiety symptoms
The outcome is measured by Hamilton anxiety rating scale (HAMA) total score change. The change value of HAMA total scores at each timepoints compared to the baseline. The maximum score of HAMA is 56 and the minimum is 0. Higher scores mean a worse outcome.
Time frame: Day 0 to Day 14, Day 0 to Day 28, Day 0 to Day 56
cognition outcome
The outcome is measured by cognition task.
Time frame: Day 0 to Day 56
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Dec 2024, 28 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 28 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Escitalopram · Aripiprazole